|
Mutation Information
|
Mutation Site
|
L210W |
|
Mutation Type
|
Amino acid level |
|
Gene/Protein/Region Type
|
RT |
|
Combined Mutation
|
rt.N348I+rt.L210W |
|
Viral Reference
|
K03455.1
|
|
Relevant Drug
|
thymidineanalogue (TAMs) |
|
Country
|
UK |
Literature Information
|
PubMed PMID
|
18052601
|
|
Disease
|
HIV infection/AIDS
|
|
Published Year
|
2007 |
|
Journal
|
PLoS medicine |
|
Title
|
N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance. |
|
Author
|
Yap SH,Sheen CW,Fahey J,Zanin M,Tyssen D,Lima VD,Wynhoven B,Kuiper M,Sluis-Cremer N,Harrigan PR,Tachedjian G |
|
Evidence
|
N348I was highly associated with several key drug resistance mutations, including M184V/I (p = 6.6 x 10-45) the TAMs M41L (p = 1.8 x 10-14), D67N (p = 7.7 x 10-10), K70R (p = 1.4 x 10-10), T215Y/F (p = 6.0 x 10-21), K219Q/E (p = 8.0 x 10-4), and L210W (p = 0.002), and the NNRTI resistance mutations K103N (p = 1.1 x 10-19), V108l (p = 8.4 x 10-13), Y181C/I (p = 4.7 x 10-13) and G190A/S (p = 8.0 x 10-9) (Figure 1).
|
|
|
HIV Mutation Detail Information